Market Overview

Benzinga's Top Downgrades

Related MNKD
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
MannKind: FDA Delays Afrezza Decision by Three Months (Fox Business)
Related NVO
Glaxo's Tanzeum Approved in the U.S. - Analyst Blog
Encouraging Results from Lexicon Candidate - Analyst Blog
Novo Nordisk Upgraded to 'Buy' (Fox Business)

Analysts at Bank of America downgraded MannKind (NASDAQ: MNKD) from “neutral” to “underperform.” The target price for MannKind has been lowered from $8 to $5. MannKind's shares closed at $6.30 yesterday.

Swedbank downgraded Novo Nordisk A/S (NYSE: NVO) from “strong buy” to “buy.” Novo Nordisk's shares closed at $162.53 yesterday.

SunTrust Robinson Humphrey downgraded Bank of the Ozarks (NASDAQ: OZRK) from “buy” to “neutral.” The target price for Bank of the Ozarks has been raised from $46 to $49. Bank of the Ozarks' shares closed at $46.01 yesterday.

Analysts at Credit Suisse downgraded M&T Bank (NYSE: MTB) from “outperform” to “neutral.” M&T Bank's shares closed at $115.91 yesterday.

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Most Popular

Related Articles (MNKD + MTB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free